Company news

Bristol-Myers Squibb Company news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Bristol Myers Squibb Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

March 29, 2026

Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy™ (xanomeline and trospium chloride)

March 28, 2026

A New Era in Schizophrenia Care: National Council for Mental Wellbeing and Bristol Myers Squibb Collaborate to Advance Evidence-Based Care Models

March 27, 2026

insitro and Bristol Myers Squibb Collaboration Expanded with Nomination of New Targets

March 23, 2026

Bristol Myers Squibb Reinforces Leadership in oHCM with New Camzyos (mavacamten) Data at American College of Cardiology Annual Scientific Session & Expo 2026 (ACC.26)

March 23, 2026

Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab)

March 20, 2026

Bristol Myers Squibb to Report Results for First Quarter 2026 on April 30, 2026

March 19, 2026

Colgate-Palmolive Announces Quarterly Dividend Increase and Elects Christopher Boerner, Ph.D. to Board of Directors

March 12, 2026

Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma

March 9, 2026

U.S. FDA Approves Bristol Myers Squibb’s Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis

March 6, 2026

Bristol Myers Squibb Announces Dividend

March 2, 2026

SystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

February 26, 2026

Bristol Myers Squibb to Participate in the TD Cowen 46th Annual Health Care Conference

February 23, 2026

Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha (α)-Thalassemia

February 23, 2026

Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights

February 19, 2026

Evinova Announces Strategic Collaborations with Astellas, AstraZeneca and Bristol Myers Squibb Advancing Its AI-Native Platform to Accelerate Global Clinical Development

February 18, 2026

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma

February 17, 2026

Evinova and Bristol Myers Squibb Forge Strategic Collaboration to Optimize Clinical Development with Artificial Intelligence

February 9, 2026

Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2025

February 5, 2026

Bristol Myers Squibb Teams Up with Kasey Keller to Share His Lymphoma Journey with Breyanzi

February 4, 2026

Bristol Myers Squibb Introduces "Change the Target. Change What’s Possible." to Highlight Unmet Needs in Cardiovascular and Thromboembolic Care

February 3, 2026

Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors

January 22, 2026

Bristol Myers Squibb Announces Collaboration with Microsoft to Advance AI-Driven Early Detection of Lung Cancer

January 22, 2026

Syngene International extends long-term research collaboration with Bristol Myers Squibb until 2035

January 20, 2026

BioCT Appoints Four Distinguished Life Sciences Leaders to Board of Directors

January 14, 2026

Oramed and Lifeward Announce Strategic Transaction

January 13, 2026

Bristol Myers Squibb Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

January 12, 2026

Tempus Achieves Record Total Contract Value Exceeding $1.1 Billion

January 11, 2026

Enhanced Genomics Appoints Dr Katerina Leftheris to Its Board of Directors

January 9, 2026

During J. P. Morgan Healthcare Week, Biotech Showcase™ Provides Private and Micro- to Mid-Cap Public Company Executives One-Stop Access to Investors, Pharma Partners and Media

January 8, 2026

Bristol Myers Squibb to Present at J.P. Morgan’s 44th Annual Healthcare Conference

January 2, 2026

Bristol Myers Squibb Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans

December 19, 2025

Bristol Myers Squibb to Report Results for Fourth Quarter 2025 on February 5, 2026

December 18, 2025

Harbour BioMed Enters into Global Strategic Collaboration and License Agreement with Bristol Myers Squibb to Discover and Develop Next-Generation Multi-Specific Antibodies

December 16, 2025

U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma

December 11, 2025

Bristol Myers Squibb Announces Dividend Increase

December 10, 2025

Ability Biotherapeutics Appoints Angèle Maki, PhD, as Chief Business Officer

December 9, 2025

BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer

December 9, 2025

Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025

December 8, 2025

Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)

December 4, 2025

Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease

December 3, 2025

Bristol Myers Squibb Data at ASH 2025 Showcase Potential of Hematology Pipeline and Build Momentum for Next Generation Portfolio

December 1, 2025

Bristol Myers Squibb to Participate in Citi’s 2025 Global Healthcare Conference

November 26, 2025

Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma

November 24, 2025

Bristol Myers Squibb to Host Hematology-Focused Investor Event

November 24, 2025

Ability Biotherapeutics Expands its Scientific Advisory Board with the Appointment of Dr. John Burke and Dr. Alan Korman

November 19, 2025

Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of its Tender Offers

November 18, 2025

Bristol Myers Squibb Announces Early Participation Results, Amendment and Early Settlement of Tender Offers

November 17, 2025

Update on Phase 3 Librexia ACS Trial

November 14, 2025

Sarah Cannon Research Institute and Bristol Myers Squibb Expand Strategic Collaboration to Accelerate Patient Enrollment and Broaden Access to Innovative Cancer Research

November 12, 2025

← Newer news releases · Older news releases →

Calls

The 5 newest of 31 calls. Every call is listed under its year.

Decks

The 5 newest of 64 decks. Every deck is listed under its year.